# US 2012/0251530 A1 · Combination therapy of her expressing tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251530 A1
- Document ID: US20120251530A1
- Status: Published application
- Kind: A1
- Application number: 13/413,062
- Filed: 2012-03-06
- Published: 2012-10-04
- Earliest claimed: 2005-07-22
- Inventors: Mark X Sliwkowski; Stephen M. Kelsey
- Web page: https://patentgrep.com/patent/US20120251530A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 239/86: with hetero atoms directly attached in position 4
- C07D 239/94: Nitrogen atoms
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.

## Claims

### Claim 1

A method for the treatment of tumor comprising administering to a human subject with a tumor expressing EGFR and HER2, an effective amount of a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's tumor does not show a complete response to treatment with said HER2 dimerization inhibitor or said EGFR inhibitor when administered as a single agent.

### Claim 2 (depends on 1)

The method of claim 1 wherein said tumor shows a partial response to treatment with said EGFR inhibitor administered as a single agent.

### Claim 3 (depends on 1)

The method of claim 1 wherein said tumor shows a partial response to treatment with said HER2-dimerization inhibitor administered as a single agent.

### Claim 4 (depends on 1)

The method of claim 1 wherein said tumor additionally expresses HER3.

### Claim 5 (depends on 1)

The method of claim 1 wherein said tumor is refractory to chemotherapy and/or radiation therapy.

### Claim 6 (depends on 1)

The method of claim 1 wherein said tumor displays HER2 receptor overexpression or amplification.

### Claim 7 (depends on 1)

The method of claim 1 wherein said tumor does not display HER2 receptor overexpression or amplification.

### Claim 8 (depends on 1)

The method of claim 1 wherein said treatment increases the time to tumor progression and/or the time to death relative to treatment with said HER2 dimerization inhibitor or said EGFR inhibitor when administered as a single agent.

### Claim 9 (depends on 1)

The method of claim 1 wherein said tumor is selected from the group consisting of lung cancer, prostate cancer and colon cancer.

### Claim 10 (depends on 9)

The method of claim 9 wherein said tumor is lung cancer.

### Claim 11 (depends on 10)

The method of claim 10 wherein said lung cancer is selected from the group consisting of small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung, and squamous carcinoma of the lung.

### Claim 12 (depends on 11)

The method of claim 11 wherein said lung cancer is non-small cell lung cancer (NSCLC).

### Claim 13 (depends on 12)

The method of claim 12 wherein said NSCLC said treatment is provided as a second or third line therapy.

### Claim 14 (depends on 9)

The method of claim 9 wherein said cancer is pancreatic cancer.

### Claim 15 (depends on 14)

The method of claim 14 further comprising the administration of gemcitabine.

### Claim 16 (depends on 9)

The method of claim 9 wherein said cancer is colon cancer.

### Claim 17 (depends on 16)

The method of claim 16 wherein said treatment is provided as a third line therapy.

### Claim 18 (depends on 16)

The method of claim 16 wherein said human subject in unsuitable for chemotherapy.

### Claim 19 (depends on 1)

The method of claim 1 wherein said HER2 dimerization inhibitor is a HER2 antibody.

### Claim 20 (depends on 19)

The method of claim 19 wherein said HER2 antibody binds to domain II of HER2 extracellular domain.

### Claim 21 (depends on 19)

The method of claim 19 wherein said HER2 antibody binds to a junction between domains I, II and III of HER2 extracellular domain.

### Claim 22 (depends on 19)

The method of claim 19 wherein said HER2 antibody is a humanized 2C4 antibody.

### Claim 23 (depends on 22)

The method of claim 22 wherein said HER2 antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 11 and 12, respectively.

### Claim 24 (depends on 23)

The method of claim 23 wherein said HER2 antibody is rhuMAb 2C4 (pertuzumab).

### Claim 25 (depends on 1)

The method of claim 1 wherein said EGFR inhibitor is a non-peptide small molecule.

### Claim 26 (depends on 1)

The method of claim 1 wherein said EGFR inhibitor is an EGFR antibody.

### Claim 27 (depends on 1)

The method of claim 1 wherein said EGFR inhibitor blocks the formation of EGFR-EGFR homodimers but not the formation of EGFR-HER2 heterodimers.

### Claim 28 (depends on 27)

The method of claim 27 wherein said EGFR inhibitor has formula I:
wherein:
X is halo or hydroxy;
m is 1, 2, or 3;
each R1 is independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxyamino, carboxy, nitro, guanidino, ureido, cyano, trifluoromethyl, and —(C1-C4 alkylene)-W-(phenyl) wherein W is a single bond, O, S or NH;
or each R1 is independently selected from R9 and C1-C4 alkyl substituted by cyano, wherein R9 is selected from the group consisting of R5, —OR6, —NR6R6, —C(O)R7, —NHOR5, —OC(O)R6, cyano, A and —YR5; R5 is C1-C4 alkyl; R6 is independently hydrogen or R5; R7 is R5, —OR6 or —NR6R6; A is selected from piperidino, morpholino, pyrrolidino, 4-R6-piperazin-1-yl, imidazol-1-yl, 4-pyridon-1-yl, —(C1-C4 alkylene)(CO2H), phenoxy, phenyl, phenylsulfanyl, C2-C4 alkenyl, and —(C1-C4 alkylene)C(O)NR6R6; and Y is S, SO, or SO2;
wherein the alkyl moieties in R5, —OR6 and —NR6R6 are optionally substituted by one to three halo substituents and the alkyl moieties in R5, —OR6 and —NR6R6 are optionally substituted by 1 or 2 R9 groups, and wherein the alkyl moieties of said optional substituents are optionally substituted by halo or R9, with the proviso that two heteroatoms are not attached to the same carbon atom;
or each R1 is independently selected from —NHSO2R5, phthalimido-(C1-C4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R10—(C2-C4)-alkanoylamino wherein R10 is selected from halo, —OR6, C2-C4 alkanoyloxy, —C(O)R7, and —NR6R6; and wherein said —NHSO2R5, phthalimido-(C1-C4-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R10—(C2-C4)-alkanoylamino R1 groups are optionally substituted by 1 or 2 substituents independently selected from halo, C1-C4 alkyl, cyano, methanesulfonyl and C1-C4 alkoxy;
or two R1 groups are taken together with the carbons to which they are attached to form a 5-8 membered ring that includes 1 or 2 heteroatoms selected from O, S and N;
R2 is hydrogen or C1-C6 alkyl optionally substituted by 1 to 3 substituents independently selected from halo, C1-C4 alkoxy, —NR6R6, and —SO2R5;
n is 1 or 2 and each R3 is independently selected from hydrogen, halo, hydroxy, C1-C6 alkyl, —NR6R6, and C1-C4 alkoxy, wherein the alkyl moieties of said R3 groups are optionally substituted by 1 to 3 substituents independently selected from halo, C1-C4 alkoxy, —NR6R6, and —SO2R; and,
R4 is azido or -(ethynyl)-R11 wherein R11 is hydrogen or C1-C6 alkyl optionally substituted by hydroxy, —OR6, or —NR6R6.

### Claim 29 (depends on 28)

The method of claim 28 wherein the EGFR inhibitor is a compound of formula I selected from the group consisting of:
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; (6,7-dimethoxyquinazolin-4-yl)-[3-(3′-hydroxypropyn-1-yl)phenyl]-amine; [3-(2′-(aminomethyl)-ethynyl)phenyl]-(6,7-dimethoxyquinazolin-4-yl)-amine; (3-ethynylphenyl)-(6-nitroquinazolin-4-yl)-amine; (6,7-dimethoxyquinazolin-4-yl)-(4-ethynylphenyl)-amine; (6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-2-methylphenyl)-amine; (6-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-(6-methanesulfonylaminoquinazolin-4-yl)-amine; (3-ethynylphenyl)-(6,7-methylenedioxyquinazolin-4-yl)-amine; (6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-6-methylphenyl)-amine; (3-ethynylphenyl)-(7-nitroquinazolin-4-yl)-amine; (3-ethynylphenyl)-[6-(4′-toluenesulfonylamino)quinazolin-4-yl]-amine; (3-ethynylphenyl)-{6-[2′-phthalimido-eth-1′-yl-sulfonylamino]quinazolin-4-yl}-amine; (3-ethynylphenyl)-(6-guanidinoquinazolin-4-yl)-amine; (7-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-(7-methoxyquinazolin-4-yl)-amine; (6-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; (7-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; [6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)-amine; (3-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (3-azido-5-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (4-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (3-ethynylphenyl)-(6-methansulfonyl-quinazolin-4-yl)-amine; (6-ethansulfanyl-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6,7-dimethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine; (6,7-dimethoxy-quinazolin-4-yl)-[3-(propyn-1′-yl)-phenyl]-amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(5-ethynyl-2-methyl-phenyl)-amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-4-fluoro-phenyl)-amine; [6,7-bis-(2-chloro-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; [6-(2-chloro-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; [6,7-bis-(2-acetoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 2-[4-(3-ethynyl-phenylamino)-7-(2-hydroxy-ethoxy)-quinazolin-6-yloxy]-ethanol; [6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; [7-(2-chloro-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; [7-(2-acetoxy-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 2-[4-(3-ethynyl-phenylamino)-6-(2-hydroxy-ethoxy)-quinazolin-7-yloxy]-ethanol; 2-[4-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yloxy]-ethanol; 2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol; [6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; (3-ethynyl-phenyl)-{6-(2-methoxy-ethoxy)-7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-quinazolin-4-yl}-amine; (3-ethynyl-phenyl)-[7-(2-methoxy-ethoxy)-6-(2-morpholin-4-yl)-ethoxy)-quinazolin-4-yl]-amine; (6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (6,7-dibutoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (6,7-diisopropoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (6,7-diethoxyquinazolin-1-yl)-(3-ethynyl-2-methyl-phenyl)-amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynyl-2-methyl-phenyl)-amine; (3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-1-yl]-amine; [6,7-bis-(2-hydroxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; 2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol; (6,7-dipropoxy-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(3-ethynyl-5-fluoro-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(5-ethynyl-2-methyl-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(3-ethynyl-4-methyl-phenyl)-amine; (6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine; (6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylmethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylmethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylmethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; and (6-aminocarbonylethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-1-yl]-amine; [6,7-bis-(2-hydroxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; (6,7-dimethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-(6-methanesulfonylamino-quinazolin-1-yl)-amine; and (6-amino-quinazolin-1-yl)-(3-ethynylphenyl)-amine.

### Claim 30 (depends on 28)

The method of claim 28 wherein the EGFR inhibitor of formula I is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine.

### Claim 31 (depends on 30)

The method of claim 30 wherein the EGFR inhibitor N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine is an HCl salt form.

### Claim 32 (depends on 31)

The method of claim 31 wherein the EGFR inhibitor N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine is erlotinib, which is present in a substantially homogeneous crystalline polymorph form that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at approximately 6.26, 12.48, 13.39, 16.96, 20.20, 21.10, 22.98, 24.46, 25.14 and 26.91.

### Claim 33 (depends on 1)

The method of claim 1 wherein the EGFR inhibitor blocks the formation of EGFR-EGFR homodimers and EGFR-HER2 heterodimers.

### Claim 34 (depends on 33)

The method of claim 33 wherein said EGFR inhibitor is an EGFR antibody.

### Claim 35 (depends on 34)

The method of claim 34 wherein said EGFR antibody is cetuximab.

### Claim 36 (depends on 1)

The method of claim 1 comprising administering to said human subject an effective amount of pertuzumab and erlotinib.

### Claim 37 (depends on 36)

The method of claim 36 wherein said pertuzumab and erlotinib exhibit a synergistic anti-tumor activity.

### Claim 38 (depends on 36)

The method of claim 36 wherein said cancer is non-small cell lung carcinoma (NSCLC).

### Claim 39 (depends on 38)

The method of claim 38 wherein said cancer is metastatic NSCLC.

### Claim 40 (depends on 39)

The method of claim 39 wherein said cancer is poor-risk stage 11 or stage III NSCLC.

### Claim 41 (depends on 36)

The method of claim 36 wherein said cancer is pancreatic cancer.

### Claim 42 (depends on 36)

The method of claim 36 wherein said cancer is ovarian cancer.

### Claim 43 (depends on 36)

The method of claim 36 wherein said cancer is breast cancer.

### Claim 44 (depends on 1)

The method of claim 1 comprising administering to said patient an effective amount of pertuzumab and cetuximab.

### Claim 45 (depends on 44)

The method of claim 44 wherein said pertuzumab and cetuximab exhibit a synergistic anti-tumor activity.

### Claim 46 (depends on 44)

The method of claim 44 wherein said cancer is colorectal cancer.

### Claim 47 (depends on 46)

The method of claim 46 wherein said colorectal cancer is colon cancer.

### Claim 48 (depends on 47)

The method of claim 47 wherein said colon cancer is metastatic colon cancer.

### Claim 49 (depends on 48)

The method of claim 48 wherein said colon cancer is stage II-stage IV colon cancer.

### Claim 50 (depends on 47)

The method of claim 47 wherein said colon cancer is unsuitable for chemotherapy.

### Claim 51 (depends on 44)

The method of claim 44 wherein said cancer is breast cancer.

### Claim 52 (depends on 1)

The method of claim 1 wherein said HER2 dimerization inhibitor and said EGFR inhibitor are administered simultaneously.

### Claim 53 (depends on 1)

The method of claim 1 wherein said HER2 dimerization inhibitor and said EGFR inhibitor are administered consecutively.

### Claim 54 (depends on 1)

The method of claim 1 further comprising treating said patient with at least one chemotherapeutic agents.

### Claim 55 (depends on 1)

The method of claim 1 further comprising subjecting said patient to radiation therapy.

### Claim 56 (depends on 1)

The method of claim 1 further comprising subjecting said patient to standard of care treatment.

### Claim 57

A method for the treatment of cancer comprising administering to a human subject, an effective amount of a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's cancer is not driven solely by EGFR, and the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), pancreatic cancer, and colon cancer.

### Claim 58

A method for the treatment of cancer comprising administering to a human subject an effective amount of pertuzumab and erlotinib, wherein the subject's cancer is not driven solely by EGFR, and the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), pancreatic cancer, and colon cancer.

### Claim 59

A method for the treatment of EGFR and HER2 expressing cancer comprising administering to a human subject, an effective amount of a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's cancer is refractory or responds poorly to an EGFR inhibitor.

### Claim 60

A method for the treatment of EGFR and HER2 expressing cancer comprising administering to a human subject, an effective amount of a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's tumor s refractory or responds poorly to a HER2-dimerization inhibitor.
